The most commonly mutated genes in colorectal cancer are the Adenomatous polyposis coli (APC), Tumor protein p53 (TP53), and Kirsten rat sarcoma viral oncogene homolog (KRAS) genes, but there are many other gene mutations that, alone or in combination, could be used to predict the rectal cancer response to radiotherapy or chemoradiotherapy. Here, TP53 is linked to rectal cancer.